Cambridge Investment Research Advisors
NVO

Cambridge Investment Research Advisors’s Novo Nordisk NVO Stock Holding History

Cambridge Investment Research Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.61M Sell
117,033
-25,213
-18% -$1.08M 0.01% 978
2026
Q1 		$5.23M Sell
142,246
-4,615
-3% -$219K 0.01% 945
2025
Q4 		$7.47M Sell
146,861
-2,767
-2% -$141K 0.02% 718
2025
Q3 		$8.3M Sell
149,628
-58,341
-28% -$3.41M 0.02% 650
2025
Q2 		$14.4M Buy
207,969
+47,243
+29% +$3.21M 0.04% 422
2025
Q1 		$11.2M Sell
160,726
-26,945
-14% -$2.23M 0.04% 467
2024
Q4 		$16.1M Sell
187,671
-58,297
-24% -$6.3M 0.05% 332
2024
Q3 		$29.3M Sell
245,968
-27,668
-10% -$3.69M 0.1% 198
2024
Q2 		$39.1M Buy
273,636
+76,422
+39% +$10.1M 0.14% 132
2024
Q1 		$25.3M Buy
197,214
+30,782
+18% +$3.66M 0.1% 199
2023
Q4 		$17.2M Buy
166,432
+24,479
+17% +$2.42M 0.07% 263
2023
Q3 		$12.9M Buy
141,953
+28,091
+25% +$2.47M 0.06% 307
2023
Q2 		$9.21M Buy
113,862
+8,436
+8% +$689K 0.04% 410
2023
Q1 		$8.39M Sell
105,426
-1,888
-2% -$134K 0.04% 424
2022
Q4 		$7.26M Buy
107,314
+10,148
+10% +$595K 0.04% 456
2022
Q3 		$4.84M Buy
97,166
+804
+0.8% +$43.1K 0.03% 582
2022
Q2 		$5.37M Sell
96,362
-12,640
-12% -$701K 0.03% 558
2022
Q1 		$6.05M Sell
109,002
-238
-0.2% -$12.2K 0.03% 553
2021
Q4 		$6.12M Buy
109,240
+16,932
+18% +$917K 0.03% 567
2021
Q3 		$4.43M Sell
92,308
-520
-0.6% -$25.1K 0.02% 663
2021
Q2 		$3.89M Buy
92,828
+15,726
+20% +$610K 0.02% 743
2021
Q1 		$2.6M Buy
77,102
+5,732
+8% +$204K 0.01% 882
2020
Q4 		$2.49M Buy
71,370
+1,742
+3% +$60.2K 0.01% 814
2020
Q3 		$2.42M Buy
69,628
+900
+1% +$30K 0.02% 714
2020
Q2 		$2.25M Sell
68,728
-11,902
-15% -$380K 0.02% 719
2020
Q1 		$2.43M Sell
80,630
-40,226
-33% -$1.2M 0.02% 594
2019
Q4 		$3.5M Buy
120,856
+466
+0.4% +$12.9K 0.03% 591
2019
Q3 		$3.11M Sell
120,390
-11,844
-9% -$299K 0.03% 586
2019
Q2 		$3.38M Buy
132,234
+3,854
+3% +$95.2K 0.03% 533
2019
Q1 		$3.36M Sell
128,380
-4,664
-4% -$115K 0.03% 514
2018
Q4 		$3.06M Buy
133,044
+1,208
+0.9% +$26.8K 0.03% 480
2018
Q3 		$3.11M Buy
131,836
+6,988
+6% +$171K 0.03% 514
2018
Q2 		$2.88M Sell
124,848
-6,426
-5% -$153K 0.03% 521
2018
Q1 		$3.23M Buy
131,274
+8,076
+7% +$212K 0.04% 454
2017
Q4 		$3.31M Buy
123,198
+1,838
+2% +$46.7K 0.04% 422
2017
Q3 		$2.92M Buy
121,360
+22,412
+23% +$506K 0.04% 414
2017
Q2 		$2.12M Buy
98,948
+13,598
+16% +$274K 0.03% 500
2017
Q1 		$1.46M Buy
85,350
+16,986
+25% +$296K 0.03% 570
2016
Q4 		$1.23M Buy
68,364
+1,374
+2% +$24.9K 0.02% 591
2016
Q3 		$1.39M Buy
66,990
+4,968
+8% +$123K 0.03% 548
2016
Q2 		$1.67M Sell
62,022
-4,628
-7% -$127K 0.04% 422
2016
Q1 		$1.81M Sell
66,650
-7,526
-10% -$202K 0.04% 379
2015
Q4 		$2.15M Sell
74,176
-488
-0.7% -$13.5K 0.05% 338
2015
Q3 		$2.02M Sell
74,664
-6,552
-8% -$186K 0.06% 307
2015
Q2 		$2.22M Sell
81,216
-48,436
-37% -$1.36M 0.06% 291
2015
Q1 		$3.46M Buy
129,652
+3,818
+3% +$87.9K 0.1% 207
2014
Q4 		$2.66M Buy
125,834
+17,676
+16% +$395K 0.08% 232
2014
Q3 		$2.58M Buy
108,158
+3,806
+4% +$87.6K 0.08% 258
2014
Q2 		$2.41M Sell
104,352
-2,972
-3% -$65.6K 0.08% 237
2014
Q1 		$2.45M Buy
107,324
+7,424
+7% +$158K 0.09% 207
2013
Q4 		$1.85M Buy
99,900
+7,490
+8% +$131K 0.08% 255
2013
Q3 		$1.56M Buy
92,410
+21,160
+30% +$356K 0.07% 261
2013
Q2 		$1.1M Buy
+71,250
New +$1.19M 0.06% 298

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Cambridge Investment Research Advisors's NVO Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its Novo Nordisk (NVO) stake by 18% in Q2 2026, selling an estimated $1.08M and leaving 117,033 shares worth $5.61M. The position accounts for 0.01% of the portfolio, ranked #978.

Cambridge Investment Research Advisors first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $39.1M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Cambridge Investment Research Advisors held 117,033 shares of Novo Nordisk worth $5.61M as of Q2 2026.
  • Cambridge Investment Research Advisors sold 25,213 Novo Nordisk shares in Q2 2026, an estimated $1.08M.
  • Novo Nordisk made up 0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #978 holding.
  • Cambridge Investment Research Advisors first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
  • Cambridge Investment Research Advisors's Novo Nordisk position peaked at $39.1M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.